Search

Search Language

日本語 / Japanese | Use language selector above (below, on mobile) to search additional languages

Open filter

Selected filters
x(Life Sciences & HealthTech)

110 items matching filters

Insight

Managing and Maintaining Clinical Trial Disclosure for Publicly Traded Life Sciences Companies

by Albert Vanderlaan | May.21.2020

The following discussion is intended to help guide companies in making clinical trial-related disclosures.

Insight

Direct Listings May Pose Challenges for Cash Intensive Life Sciences Companies

by Albert Vanderlaan | May.14.2020

Are direct listings a viable potential alternative for all companies seeking to go public? The answer may likely be no.

Insight

Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q1 2020

May.11.2020

The Market Meets COVID-19
In this new series, we explore trends in venture investing across the life sciences sector.

Insight

CARES Act Small Business Loans

March.30.2020

We summarize key points of the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) most relevant to tech and life sciences startups.

Insight

17 Mistakes Startups Make with Their Investor Pitch Deck

July.29.2019

Orrick’s Technology and Life Sciences Sector Leader Don Keller co-authored an article in Forbes with Orrick alum Richard Harroch.

Insight

Profiles in Innovation: Twist Bioscience’s Co-Founder Navigates Company from Start-up to Public Company

February.21.2019

Emily Leproust discusses her inspiration and journey building a public company in the fast growing synthetic DNA market with commentary from Orrick ...

Insight

Scope of Estoppel Post-IPR Proceedings Becoming Clearer

by K. Patrick Herman | March.27.2017

This estoppel provision has been the subject of a number of Federal Circuit and district court decisions.

Insight

Quo Vadis FTC: What Does the Commission's Complaint Against Endo Pharmaceuticals and Others Say About the Future of Post-Actavis Hatch-Waxman Litigation and Reverse Payment Settlements?

by Robert Reznick | April.07.2016

This alert, the title of which is adapted from a March 30, 2016 FTC Staff Attorney blog post, considers the FTC’s first lawsuit challenging a ...

Insight

Post-Grant Proceedings Complicate Pharmaceutical Litigation

April.04.2016

Since the passage of the America Invents Act in 2011, various changes to the patent litigation landscape have occurred.

Insight

1st Circ. Charts Conservative Post-Actavis Course In Loestrin

by Robert Reznick | February.26.2016

Members of Orrick’s Antitrust & Competition team co-authored an article on a recent First Circuit decision concerning "reverse payment" settlements ...

Insight

District Court Finds No Personal Jurisdiction over Malaysian Company Acting as Receiver of Malaysian Subsidiary of U.S.-Based Biotechnology Company

January.19.2016

Viropro, Inc., v. PriceWaterhouseCoopers Advisory Services Sdn Bhd, U.S. District Court for the Southern District of New York, January 19, ...

Insight

District Court Finds No Personal Jurisdiction over Swedish Manufacturer of Pharmaceutical Product That Knew its Products Were Resold to U.S. Customers

January.05.2016

Novotec Pharma LLC, v. Glycobiosciences, Inc., U.S. District Court for the District of New Jersey, January 5, 2016 The complicated history of this ...